| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 190 | 2023 | 5319 | 7.880 |
Why?
|
| Lung Neoplasms | 244 | 2023 | 11538 | 7.580 |
Why?
|
| Esophageal Neoplasms | 114 | 2023 | 3168 | 5.600 |
Why?
|
| Small Cell Lung Carcinoma | 20 | 2023 | 406 | 4.260 |
Why?
|
| Chemoradiotherapy | 61 | 2020 | 1946 | 3.880 |
Why?
|
| Radiation Pneumonitis | 35 | 2018 | 301 | 3.710 |
Why?
|
| Radiotherapy, Intensity-Modulated | 49 | 2020 | 2104 | 3.670 |
Why?
|
| Radiotherapy, Conformal | 43 | 2020 | 902 | 2.750 |
Why?
|
| Radiosurgery | 31 | 2020 | 1330 | 2.570 |
Why?
|
| Cranial Irradiation | 14 | 2020 | 315 | 2.240 |
Why?
|
| Radiotherapy Dosage | 100 | 2023 | 3842 | 2.150 |
Why?
|
| Proton Therapy | 39 | 2020 | 1577 | 2.060 |
Why?
|
| Adenocarcinoma | 71 | 2018 | 7789 | 1.940 |
Why?
|
| Lung | 38 | 2016 | 3151 | 1.920 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 45 | 2018 | 2370 | 1.880 |
Why?
|
| Radiation Injuries | 37 | 2018 | 1411 | 1.820 |
Why?
|
| Combined Modality Therapy | 111 | 2021 | 8865 | 1.650 |
Why?
|
| Neoplasm Staging | 112 | 2020 | 13658 | 1.550 |
Why?
|
| Aged | 258 | 2020 | 70117 | 1.530 |
Why?
|
| Carcinoma, Squamous Cell | 44 | 2017 | 5437 | 1.520 |
Why?
|
| Aged, 80 and over | 159 | 2020 | 29902 | 1.520 |
Why?
|
| Esophagectomy | 31 | 2018 | 911 | 1.450 |
Why?
|
| Organs at Risk | 13 | 2017 | 514 | 1.450 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 71 | 2023 | 15862 | 1.450 |
Why?
|
| Middle Aged | 268 | 2023 | 86204 | 1.430 |
Why?
|
| Neoplasm Recurrence, Local | 47 | 2018 | 10035 | 1.350 |
Why?
|
| Male | 293 | 2023 | 123000 | 1.270 |
Why?
|
| Esophagitis | 17 | 2018 | 202 | 1.260 |
Why?
|
| Amifostine | 12 | 2013 | 97 | 1.250 |
Why?
|
| Carcinoma, Small Cell | 10 | 2014 | 408 | 1.240 |
Why?
|
| Positron-Emission Tomography | 29 | 2020 | 2173 | 1.210 |
Why?
|
| Female | 295 | 2023 | 141928 | 1.190 |
Why?
|
| Humans | 405 | 2023 | 261506 | 1.170 |
Why?
|
| Tomography, X-Ray Computed | 47 | 2020 | 7551 | 1.130 |
Why?
|
| Adult | 201 | 2020 | 77950 | 1.110 |
Why?
|
| Fluorodeoxyglucose F18 | 20 | 2017 | 1226 | 1.070 |
Why?
|
| Radiation-Protective Agents | 9 | 2011 | 128 | 1.010 |
Why?
|
| Radiopharmaceuticals | 16 | 2017 | 1301 | 1.000 |
Why?
|
| Paclitaxel | 29 | 2019 | 1996 | 1.000 |
Why?
|
| Brain Neoplasms | 23 | 2020 | 4849 | 0.990 |
Why?
|
| Respiration | 11 | 2014 | 447 | 0.910 |
Why?
|
| Movement | 14 | 2016 | 556 | 0.890 |
Why?
|
| Mesothelioma | 9 | 2016 | 544 | 0.890 |
Why?
|
| Carboplatin | 19 | 2019 | 823 | 0.880 |
Why?
|
| ErbB Receptors | 9 | 2015 | 2295 | 0.870 |
Why?
|
| Retrospective Studies | 116 | 2020 | 37905 | 0.860 |
Why?
|
| Thymus Neoplasms | 9 | 2016 | 400 | 0.860 |
Why?
|
| Quinazolines | 10 | 2015 | 923 | 0.840 |
Why?
|
| Tumor Burden | 24 | 2017 | 1987 | 0.830 |
Why?
|
| Survival Rate | 57 | 2020 | 12221 | 0.810 |
Why?
|
| Treatment Outcome | 104 | 2021 | 32848 | 0.790 |
Why?
|
| Induction Chemotherapy | 10 | 2018 | 669 | 0.780 |
Why?
|
| Cisplatin | 30 | 2021 | 2432 | 0.760 |
Why?
|
| Disease-Free Survival | 47 | 2023 | 10001 | 0.750 |
Why?
|
| Radiotherapy, Adjuvant | 26 | 2020 | 2231 | 0.740 |
Why?
|
| Proportional Hazards Models | 31 | 2018 | 4988 | 0.740 |
Why?
|
| Thymoma | 7 | 2016 | 246 | 0.730 |
Why?
|
| Pleural Neoplasms | 8 | 2016 | 470 | 0.720 |
Why?
|
| Esophagogastric Junction | 13 | 2017 | 543 | 0.720 |
Why?
|
| Radiation Oncology | 3 | 2014 | 529 | 0.660 |
Why?
|
| Analysis of Variance | 24 | 2017 | 2307 | 0.660 |
Why?
|
| Prognosis | 67 | 2020 | 21713 | 0.660 |
Why?
|
| Fluorouracil | 17 | 2017 | 1944 | 0.660 |
Why?
|
| Survival Analysis | 51 | 2020 | 9180 | 0.660 |
Why?
|
| Follow-Up Studies | 56 | 2020 | 14889 | 0.640 |
Why?
|
| Nuclear Warfare | 1 | 2017 | 2 | 0.630 |
Why?
|
| Radiotherapy | 20 | 2016 | 1824 | 0.630 |
Why?
|
| Etoposide | 16 | 2021 | 870 | 0.630 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2017 | 24 | 0.630 |
Why?
|
| Neutrophils | 3 | 2018 | 835 | 0.600 |
Why?
|
| Leukopenia | 1 | 2017 | 151 | 0.600 |
Why?
|
| Pneumonectomy | 12 | 2018 | 831 | 0.600 |
Why?
|
| Lymphocytes | 3 | 2018 | 1234 | 0.600 |
Why?
|
| Radiation-Sensitizing Agents | 7 | 2016 | 363 | 0.600 |
Why?
|
| Dose-Response Relationship, Radiation | 15 | 2019 | 726 | 0.590 |
Why?
|
| Radiobiology | 2 | 2013 | 56 | 0.560 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2018 | 4549 | 0.540 |
Why?
|
| Lymphopenia | 5 | 2018 | 199 | 0.530 |
Why?
|
| Pneumonia | 8 | 2017 | 751 | 0.530 |
Why?
|
| Neoadjuvant Therapy | 24 | 2018 | 4975 | 0.520 |
Why?
|
| Antineoplastic Agents | 30 | 2018 | 14289 | 0.510 |
Why?
|
| Carcinoma, Neuroendocrine | 3 | 2016 | 716 | 0.500 |
Why?
|
| Chemoradiotherapy, Adjuvant | 7 | 2018 | 565 | 0.490 |
Why?
|
| Bronchial Neoplasms | 2 | 2006 | 79 | 0.490 |
Why?
|
| Prospective Studies | 35 | 2023 | 12873 | 0.480 |
Why?
|
| Kaplan-Meier Estimate | 27 | 2020 | 6207 | 0.480 |
Why?
|
| Neutropenia | 2 | 2017 | 968 | 0.470 |
Why?
|
| Spinal Cord | 9 | 2012 | 690 | 0.460 |
Why?
|
| Respiratory Mechanics | 4 | 2014 | 173 | 0.460 |
Why?
|
| Chemotherapy, Adjuvant | 26 | 2017 | 3890 | 0.460 |
Why?
|
| Multivariate Analysis | 22 | 2018 | 4298 | 0.460 |
Why?
|
| Leukemia, Myeloid | 1 | 2017 | 941 | 0.430 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 846 | 0.430 |
Why?
|
| Treatment Failure | 15 | 2018 | 1391 | 0.420 |
Why?
|
| Re-Irradiation | 3 | 2018 | 163 | 0.420 |
Why?
|
| Anemia | 1 | 2017 | 689 | 0.410 |
Why?
|
| Radiation Tolerance | 10 | 2017 | 629 | 0.410 |
Why?
|
| Heart | 11 | 2017 | 1223 | 0.410 |
Why?
|
| Brachytherapy | 4 | 2007 | 977 | 0.410 |
Why?
|
| Neoplasm Metastasis | 17 | 2018 | 5112 | 0.400 |
Why?
|
| Diffusion of Innovation | 1 | 2012 | 160 | 0.400 |
Why?
|
| Salvage Therapy | 8 | 2018 | 2054 | 0.400 |
Why?
|
| Esophagus | 11 | 2014 | 553 | 0.380 |
Why?
|
| Radiometry | 6 | 2012 | 980 | 0.370 |
Why?
|
| Cetuximab | 7 | 2023 | 472 | 0.370 |
Why?
|
| Lymphatic Metastasis | 23 | 2016 | 4844 | 0.370 |
Why?
|
| Radiotherapy, Image-Guided | 5 | 2017 | 304 | 0.350 |
Why?
|
| Feasibility Studies | 12 | 2018 | 2292 | 0.350 |
Why?
|
| Global Health | 1 | 2014 | 657 | 0.340 |
Why?
|
| Drug Administration Schedule | 10 | 2015 | 3472 | 0.340 |
Why?
|
| Esophagoscopy | 4 | 2012 | 291 | 0.340 |
Why?
|
| Heart Septal Defects | 1 | 2009 | 51 | 0.340 |
Why?
|
| Postoperative Complications | 8 | 2017 | 5542 | 0.330 |
Why?
|
| Remission Induction | 8 | 2018 | 3569 | 0.330 |
Why?
|
| Imaging, Three-Dimensional | 9 | 2015 | 925 | 0.320 |
Why?
|
| Radiotherapy, Computer-Assisted | 2 | 2010 | 126 | 0.320 |
Why?
|
| Coronary Circulation | 1 | 2009 | 253 | 0.320 |
Why?
|
| Neoplasm, Residual | 8 | 2016 | 1656 | 0.320 |
Why?
|
| Myocardial Ischemia | 2 | 2009 | 435 | 0.310 |
Why?
|
| Thoracic Neoplasms | 3 | 2017 | 337 | 0.310 |
Why?
|
| Algorithms | 12 | 2014 | 3890 | 0.300 |
Why?
|
| Brachial Plexus | 3 | 2012 | 45 | 0.300 |
Why?
|
| Camptothecin | 6 | 2005 | 517 | 0.300 |
Why?
|
| Propensity Score | 8 | 2020 | 750 | 0.300 |
Why?
|
| Cyclooxygenase Inhibitors | 3 | 2005 | 177 | 0.300 |
Why?
|
| Incidence | 14 | 2020 | 5673 | 0.290 |
Why?
|
| Antibodies, Monoclonal | 5 | 2016 | 4367 | 0.290 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2008 | 361 | 0.290 |
Why?
|
| Pulmonary Diffusing Capacity | 4 | 2012 | 36 | 0.290 |
Why?
|
| Maximum Tolerated Dose | 8 | 2016 | 1290 | 0.290 |
Why?
|
| Sex Characteristics | 1 | 2009 | 417 | 0.290 |
Why?
|
| Four-Dimensional Computed Tomography | 6 | 2014 | 226 | 0.280 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2008 | 255 | 0.280 |
Why?
|
| Risk Factors | 26 | 2018 | 17523 | 0.280 |
Why?
|
| Lambert-Eaton Myasthenic Syndrome | 1 | 2006 | 12 | 0.280 |
Why?
|
| Drug Therapy | 1 | 2007 | 205 | 0.280 |
Why?
|
| DNA Repair Enzymes | 2 | 2017 | 237 | 0.280 |
Why?
|
| Time Factors | 22 | 2018 | 12926 | 0.280 |
Why?
|
| Pulmonary Ventilation | 1 | 2006 | 45 | 0.280 |
Why?
|
| Transforming Growth Factor beta1 | 3 | 2013 | 292 | 0.280 |
Why?
|
| Radiographic Image Enhancement | 2 | 2006 | 402 | 0.270 |
Why?
|
| Confidence Intervals | 9 | 2018 | 756 | 0.260 |
Why?
|
| Mutagenicity Tests | 1 | 2005 | 69 | 0.260 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2014 | 1303 | 0.260 |
Why?
|
| Radiography | 8 | 2012 | 1904 | 0.260 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2023 | 2594 | 0.250 |
Why?
|
| MicroRNAs | 5 | 2016 | 2947 | 0.250 |
Why?
|
| Risk Assessment | 8 | 2018 | 6869 | 0.250 |
Why?
|
| Regression Analysis | 11 | 2018 | 1546 | 0.250 |
Why?
|
| Metformin | 3 | 2020 | 378 | 0.240 |
Why?
|
| Lymph Nodes | 8 | 2017 | 2967 | 0.240 |
Why?
|
| Organ Sparing Treatments | 2 | 2016 | 277 | 0.240 |
Why?
|
| Disease Progression | 13 | 2020 | 6682 | 0.240 |
Why?
|
| Health Care Surveys | 4 | 2014 | 430 | 0.240 |
Why?
|
| Erlotinib Hydrochloride | 6 | 2015 | 388 | 0.240 |
Why?
|
| Cognition | 2 | 2008 | 968 | 0.240 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2023 | 3251 | 0.240 |
Why?
|
| Radiation Dosage | 8 | 2016 | 1014 | 0.240 |
Why?
|
| Predictive Value of Tests | 15 | 2018 | 4892 | 0.240 |
Why?
|
| Radioisotope Teletherapy | 1 | 2003 | 12 | 0.230 |
Why?
|
| Airway Obstruction | 1 | 2006 | 261 | 0.230 |
Why?
|
| Ipilimumab | 2 | 2019 | 710 | 0.230 |
Why?
|
| Internship and Residency | 1 | 2014 | 1375 | 0.230 |
Why?
|
| DNA-Binding Proteins | 6 | 2017 | 4821 | 0.220 |
Why?
|
| Age Factors | 13 | 2018 | 5377 | 0.220 |
Why?
|
| Hypoglycemic Agents | 2 | 2020 | 586 | 0.210 |
Why?
|
| Lymphocyte Count | 3 | 2018 | 486 | 0.210 |
Why?
|
| Orthopedic Fixation Devices | 1 | 2002 | 20 | 0.210 |
Why?
|
| Taxoids | 5 | 2017 | 967 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2015 | 4757 | 0.210 |
Why?
|
| Medical Illustration | 2 | 2012 | 34 | 0.210 |
Why?
|
| Pericardial Effusion | 2 | 2016 | 118 | 0.210 |
Why?
|
| Titanium | 1 | 2002 | 61 | 0.210 |
Why?
|
| Logistic Models | 7 | 2017 | 3441 | 0.200 |
Why?
|
| Cause of Death | 5 | 2018 | 752 | 0.200 |
Why?
|
| Ribs | 2 | 2012 | 91 | 0.190 |
Why?
|
| Photons | 3 | 2017 | 507 | 0.190 |
Why?
|
| Lung Injury | 2 | 2018 | 131 | 0.190 |
Why?
|
| Vinblastine | 5 | 2011 | 453 | 0.190 |
Why?
|
| Sulfonamides | 3 | 2005 | 1823 | 0.190 |
Why?
|
| Carcinoid Tumor | 1 | 2003 | 280 | 0.190 |
Why?
|
| Pancoast Syndrome | 1 | 2000 | 9 | 0.190 |
Why?
|
| Models, Biological | 2 | 2008 | 3254 | 0.180 |
Why?
|
| Quality of Life | 6 | 2016 | 4532 | 0.180 |
Why?
|
| Clinical Trials as Topic | 11 | 2018 | 3719 | 0.180 |
Why?
|
| Models, Statistical | 4 | 2017 | 1171 | 0.180 |
Why?
|
| B7-H1 Antigen | 2 | 2017 | 1022 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2013 | 419 | 0.170 |
Why?
|
| Cryptogenic Organizing Pneumonia | 2 | 2010 | 17 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 4 | 2016 | 2403 | 0.170 |
Why?
|
| Japan | 2 | 2017 | 227 | 0.170 |
Why?
|
| Neoplasms | 10 | 2018 | 15193 | 0.170 |
Why?
|
| Acute Disease | 4 | 2018 | 2422 | 0.170 |
Why?
|
| Nomograms | 2 | 2018 | 313 | 0.160 |
Why?
|
| Endosonography | 4 | 2005 | 536 | 0.160 |
Why?
|
| Lymphatic Irradiation | 4 | 2013 | 133 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2018 | 447 | 0.160 |
Why?
|
| Hepcidins | 1 | 2018 | 34 | 0.160 |
Why?
|
| Autophagy-Related Proteins | 1 | 2018 | 57 | 0.160 |
Why?
|
| United States | 11 | 2018 | 15433 | 0.160 |
Why?
|
| Multimodal Imaging | 5 | 2014 | 550 | 0.160 |
Why?
|
| Karnofsky Performance Status | 6 | 2018 | 175 | 0.160 |
Why?
|
| Cohort Studies | 14 | 2020 | 9244 | 0.160 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2018 | 142 | 0.160 |
Why?
|
| Inflammation | 3 | 2014 | 2522 | 0.150 |
Why?
|
| Pleural Effusion | 3 | 2016 | 201 | 0.150 |
Why?
|
| Preoperative Care | 11 | 2010 | 1529 | 0.150 |
Why?
|
| Sex Factors | 5 | 2014 | 2139 | 0.150 |
Why?
|
| Reproducibility of Results | 7 | 2014 | 6009 | 0.150 |
Why?
|
| Acute Lung Injury | 1 | 2018 | 92 | 0.150 |
Why?
|
| Statistics, Nonparametric | 4 | 2013 | 980 | 0.150 |
Why?
|
| Carcinoma, Large Cell | 2 | 2015 | 94 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2018 | 665 | 0.150 |
Why?
|
| Smad4 Protein | 1 | 2018 | 196 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2020 | 7702 | 0.150 |
Why?
|
| Biomarkers, Tumor | 10 | 2018 | 10331 | 0.140 |
Why?
|
| Severity of Illness Index | 7 | 2017 | 4320 | 0.140 |
Why?
|
| Area Under Curve | 2 | 2015 | 700 | 0.140 |
Why?
|
| Relative Biological Effectiveness | 6 | 2017 | 219 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2017 | 8873 | 0.140 |
Why?
|
| Sensitivity and Specificity | 8 | 2012 | 4971 | 0.140 |
Why?
|
| Clinical Protocols | 2 | 2012 | 467 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2015 | 32 | 0.140 |
Why?
|
| Insurance Coverage | 1 | 2018 | 256 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2007 | 272 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 3 | 2017 | 1350 | 0.140 |
Why?
|
| Neovascularization, Pathologic | 5 | 2013 | 1547 | 0.130 |
Why?
|
| Lung Diseases | 3 | 2017 | 717 | 0.130 |
Why?
|
| Hemoglobins | 1 | 2017 | 477 | 0.130 |
Why?
|
| Young Adult | 15 | 2019 | 21445 | 0.130 |
Why?
|
| Serous Membrane | 1 | 2015 | 9 | 0.130 |
Why?
|
| Interferon Type I | 1 | 2016 | 250 | 0.130 |
Why?
|
| Registries | 3 | 2018 | 2170 | 0.130 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2015 | 32 | 0.130 |
Why?
|
| Cell Line, Tumor | 14 | 2017 | 14551 | 0.130 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2016 | 196 | 0.130 |
Why?
|
| Guideline Adherence | 2 | 2012 | 636 | 0.130 |
Why?
|
| Radioimmunotherapy | 1 | 2015 | 119 | 0.130 |
Why?
|
| Cost of Illness | 2 | 2016 | 498 | 0.130 |
Why?
|
| Endpoint Determination | 2 | 2005 | 176 | 0.130 |
Why?
|
| Linear Models | 4 | 2017 | 1085 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2011 | 1538 | 0.120 |
Why?
|
| Organizational Objectives | 1 | 2014 | 61 | 0.120 |
Why?
|
| Acute-Phase Reaction | 1 | 2014 | 26 | 0.120 |
Why?
|
| Heart Diseases | 3 | 2017 | 732 | 0.120 |
Why?
|
| Cancer Pain | 1 | 2019 | 312 | 0.120 |
Why?
|
| Mucous Membrane | 1 | 2015 | 271 | 0.120 |
Why?
|
| Unnecessary Procedures | 1 | 2014 | 104 | 0.120 |
Why?
|
| Blood Platelets | 1 | 2018 | 731 | 0.120 |
Why?
|
| Bleomycin | 2 | 2005 | 467 | 0.120 |
Why?
|
| Glucose | 1 | 2020 | 1248 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2012 | 1248 | 0.120 |
Why?
|
| Adenoviridae | 4 | 2008 | 1459 | 0.110 |
Why?
|
| RNA, Neoplasm | 1 | 2016 | 771 | 0.110 |
Why?
|
| Polymorphism, Genetic | 2 | 2011 | 1450 | 0.110 |
Why?
|
| Diabetes Complications | 2 | 2012 | 305 | 0.110 |
Why?
|
| Protons | 5 | 2017 | 473 | 0.110 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2013 | 33 | 0.110 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2018 | 342 | 0.110 |
Why?
|
| Biopsy | 3 | 2017 | 3443 | 0.110 |
Why?
|
| Pilot Projects | 4 | 2020 | 2803 | 0.110 |
Why?
|
| Liver Neoplasms | 3 | 2019 | 4557 | 0.110 |
Why?
|
| Societies, Medical | 3 | 2014 | 1335 | 0.110 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 3 | 2008 | 205 | 0.110 |
Why?
|
| Terminology as Topic | 2 | 2014 | 414 | 0.110 |
Why?
|
| Odds Ratio | 5 | 2017 | 2316 | 0.110 |
Why?
|
| Tidal Volume | 3 | 2007 | 57 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 799 | 0.110 |
Why?
|
| Anastomosis, Surgical | 1 | 2014 | 371 | 0.110 |
Why?
|
| Tomography, Emission-Computed | 3 | 2008 | 310 | 0.110 |
Why?
|
| Texas | 7 | 2017 | 6311 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2018 | 1271 | 0.110 |
Why?
|
| Brachial Plexus Neuropathies | 1 | 2012 | 19 | 0.110 |
Why?
|
| Anatomic Landmarks | 1 | 2012 | 50 | 0.100 |
Why?
|
| Developing Countries | 1 | 2014 | 315 | 0.100 |
Why?
|
| China | 1 | 2013 | 606 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2011 | 26 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2014 | 973 | 0.100 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 3 | 2008 | 305 | 0.100 |
Why?
|
| Genotype | 7 | 2015 | 4109 | 0.100 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2016 | 489 | 0.100 |
Why?
|
| Triazoles | 1 | 2016 | 617 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2015 | 3552 | 0.100 |
Why?
|
| Piperidines | 2 | 2007 | 1035 | 0.100 |
Why?
|
| Signal Transduction | 4 | 2016 | 11965 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2013 | 441 | 0.100 |
Why?
|
| Tomography, Spiral Computed | 1 | 2012 | 133 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 7 | 2018 | 3981 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2016 | 3821 | 0.100 |
Why?
|
| Palliative Care | 4 | 2016 | 2037 | 0.100 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2011 | 1833 | 0.100 |
Why?
|
| DNA Ligases | 1 | 2011 | 63 | 0.100 |
Why?
|
| Dasatinib | 1 | 2015 | 862 | 0.100 |
Why?
|
| Forced Expiratory Volume | 3 | 2012 | 314 | 0.100 |
Why?
|
| Body Burden | 2 | 2008 | 65 | 0.100 |
Why?
|
| Skin | 3 | 2008 | 1259 | 0.100 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2011 | 66 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2013 | 574 | 0.100 |
Why?
|
| Medical Oncology | 2 | 2012 | 1423 | 0.100 |
Why?
|
| Apoptosis | 7 | 2012 | 7591 | 0.100 |
Why?
|
| Membrane Glycoproteins | 2 | 2006 | 1073 | 0.100 |
Why?
|
| Mice, Nude | 7 | 2016 | 4307 | 0.100 |
Why?
|
| Isoenzymes | 2 | 2003 | 614 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2013 | 551 | 0.090 |
Why?
|
| Dacarbazine | 1 | 2013 | 485 | 0.090 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 1375 | 0.090 |
Why?
|
| Lung Compliance | 2 | 2007 | 25 | 0.090 |
Why?
|
| Immunohistochemistry | 6 | 2014 | 7548 | 0.090 |
Why?
|
| Tissue Extracts | 1 | 2010 | 48 | 0.090 |
Why?
|
| Neoplasm Grading | 4 | 2017 | 1742 | 0.090 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2017 | 170 | 0.090 |
Why?
|
| Marital Status | 1 | 2010 | 98 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 1249 | 0.090 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 904 | 0.090 |
Why?
|
| Radiodermatitis | 1 | 2010 | 75 | 0.090 |
Why?
|
| Facility Design and Construction | 1 | 2009 | 11 | 0.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 1048 | 0.090 |
Why?
|
| Postoperative Care | 3 | 2018 | 739 | 0.090 |
Why?
|
| Bone Neoplasms | 3 | 2019 | 2576 | 0.090 |
Why?
|
| Respiratory Function Tests | 3 | 2012 | 318 | 0.090 |
Why?
|
| Mutation | 3 | 2015 | 15179 | 0.090 |
Why?
|
| Celecoxib | 3 | 2005 | 200 | 0.090 |
Why?
|
| Platinum Compounds | 3 | 2017 | 131 | 0.090 |
Why?
|
| Fluorine Radioisotopes | 1 | 2010 | 133 | 0.090 |
Why?
|
| Chest Pain | 1 | 2010 | 155 | 0.090 |
Why?
|
| Gene Expression | 1 | 2017 | 3570 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2012 | 639 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 1439 | 0.080 |
Why?
|
| Receptor, ErbB-3 | 1 | 2009 | 122 | 0.080 |
Why?
|
| Aorta | 1 | 2013 | 692 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 2232 | 0.080 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2009 | 71 | 0.080 |
Why?
|
| Electrocardiography | 1 | 2014 | 1145 | 0.080 |
Why?
|
| Fractals | 1 | 2008 | 11 | 0.080 |
Why?
|
| Benzimidazoles | 1 | 2012 | 428 | 0.080 |
Why?
|
| Risk | 4 | 2018 | 1972 | 0.080 |
Why?
|
| Carcinoma | 4 | 2012 | 2578 | 0.080 |
Why?
|
| Mice | 15 | 2016 | 34495 | 0.080 |
Why?
|
| Cell Differentiation | 2 | 2017 | 4078 | 0.080 |
Why?
|
| Ribosomal Proteins | 1 | 2008 | 118 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 984 | 0.080 |
Why?
|
| Animals | 18 | 2018 | 59536 | 0.080 |
Why?
|
| Thoracic Wall | 1 | 2010 | 183 | 0.080 |
Why?
|
| Haplotypes | 1 | 2010 | 856 | 0.080 |
Why?
|
| Weight Loss | 2 | 2009 | 627 | 0.080 |
Why?
|
| Liver | 3 | 2016 | 2961 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 327 | 0.080 |
Why?
|
| Immunotherapy | 3 | 2017 | 3341 | 0.080 |
Why?
|
| Acid Anhydride Hydrolases | 2 | 2017 | 84 | 0.080 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 1054 | 0.080 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2018 | 833 | 0.080 |
Why?
|
| Pyrazoles | 3 | 2005 | 1471 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2018 | 5539 | 0.070 |
Why?
|
| Endostatins | 1 | 2007 | 48 | 0.070 |
Why?
|
| Ifosfamide | 1 | 2008 | 344 | 0.070 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 602 | 0.070 |
Why?
|
| Length of Stay | 3 | 2017 | 1900 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2008 | 1299 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2011 | 667 | 0.070 |
Why?
|
| Nausea | 2 | 2007 | 525 | 0.070 |
Why?
|
| Radiation Protection | 2 | 2008 | 205 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2010 | 1533 | 0.070 |
Why?
|
| Psychomotor Performance | 1 | 2008 | 233 | 0.070 |
Why?
|
| Speech | 1 | 2008 | 133 | 0.070 |
Why?
|
| Preoperative Period | 2 | 2013 | 344 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2003 | 1493 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2006 | 621 | 0.070 |
Why?
|
| Decision Support Techniques | 2 | 2014 | 622 | 0.070 |
Why?
|
| Smoking | 3 | 2014 | 2440 | 0.070 |
Why?
|
| T-Lymphocytes | 2 | 2017 | 3869 | 0.070 |
Why?
|
| Ulcer | 1 | 2006 | 78 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2015 | 521 | 0.070 |
Why?
|
| Thymidylate Synthase | 1 | 2005 | 53 | 0.070 |
Why?
|
| Esophageal Diseases | 1 | 2006 | 69 | 0.070 |
Why?
|
| Oncolytic Viruses | 1 | 2008 | 204 | 0.070 |
Why?
|
| Subtraction Technique | 1 | 2006 | 141 | 0.070 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2003 | 215 | 0.070 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2015 | 1763 | 0.070 |
Why?
|
| Lung Volume Measurements | 1 | 2005 | 88 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2008 | 592 | 0.070 |
Why?
|
| Genetic Markers | 3 | 2012 | 974 | 0.060 |
Why?
|
| Probability | 4 | 2008 | 866 | 0.060 |
Why?
|
| Premedication | 1 | 2005 | 135 | 0.060 |
Why?
|
| Leukocyte Count | 2 | 2018 | 684 | 0.060 |
Why?
|
| Prevalence | 3 | 2007 | 3260 | 0.060 |
Why?
|
| A549 Cells | 2 | 2016 | 124 | 0.060 |
Why?
|
| Gene Targeting | 1 | 2006 | 292 | 0.060 |
Why?
|
| Comorbidity | 4 | 2015 | 2352 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 1823 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2014 | 2669 | 0.060 |
Why?
|
| Agranulocytosis | 1 | 2004 | 79 | 0.060 |
Why?
|
| 3' Untranslated Regions | 1 | 2005 | 343 | 0.060 |
Why?
|
| Patient Selection | 2 | 2009 | 2055 | 0.060 |
Why?
|
| Longitudinal Studies | 4 | 2016 | 1945 | 0.060 |
Why?
|
| Hedgehog Proteins | 1 | 2006 | 424 | 0.060 |
Why?
|
| Glioblastoma | 1 | 2015 | 1797 | 0.060 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 2195 | 0.060 |
Why?
|
| Brain | 3 | 2020 | 4113 | 0.060 |
Why?
|
| Spinal Neoplasms | 1 | 2009 | 631 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2012 | 2045 | 0.060 |
Why?
|
| Total Lung Capacity | 1 | 2003 | 17 | 0.060 |
Why?
|
| Metalloporphyrins | 1 | 2003 | 30 | 0.060 |
Why?
|
| Vomiting | 1 | 2005 | 354 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 852 | 0.060 |
Why?
|
| Biomarkers | 3 | 2023 | 5047 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2008 | 1529 | 0.060 |
Why?
|
| Abdomen | 3 | 2012 | 332 | 0.050 |
Why?
|
| Canada | 2 | 2016 | 429 | 0.050 |
Why?
|
| Cell Proliferation | 6 | 2015 | 7226 | 0.050 |
Why?
|
| Deoxycytidine | 1 | 2008 | 1353 | 0.050 |
Why?
|
| Radiography, Thoracic | 3 | 2011 | 462 | 0.050 |
Why?
|
| Research Design | 2 | 2011 | 1544 | 0.050 |
Why?
|
| Bayes Theorem | 2 | 2018 | 1021 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2003 | 445 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2007 | 1648 | 0.050 |
Why?
|
| Carbon Monoxide | 2 | 2012 | 64 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 2315 | 0.050 |
Why?
|
| Gastroesophageal Reflux | 1 | 2005 | 334 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 2278 | 0.050 |
Why?
|
| Thoracic Vertebrae | 2 | 2009 | 186 | 0.050 |
Why?
|
| Breast Neoplasms | 5 | 2010 | 15694 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2023 | 1331 | 0.050 |
Why?
|
| DNA Damage | 2 | 2013 | 1954 | 0.050 |
Why?
|
| Genomic Instability | 1 | 2005 | 519 | 0.050 |
Why?
|
| Blotting, Western | 4 | 2012 | 3536 | 0.050 |
Why?
|
| Carbon Dioxide | 1 | 2003 | 313 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2008 | 786 | 0.050 |
Why?
|
| Bone and Bones | 2 | 2010 | 619 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2004 | 297 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2010 | 4938 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2003 | 543 | 0.050 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2005 | 436 | 0.050 |
Why?
|
| Thymectomy | 2 | 2016 | 79 | 0.050 |
Why?
|
| Abdominal Neoplasms | 1 | 1983 | 231 | 0.050 |
Why?
|
| Deglutition Disorders | 1 | 2005 | 447 | 0.050 |
Why?
|
| Cytokines | 1 | 2010 | 2809 | 0.050 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2004 | 261 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2002 | 666 | 0.050 |
Why?
|
| Genetic Vectors | 4 | 2008 | 1694 | 0.050 |
Why?
|
| False Positive Reactions | 2 | 2014 | 355 | 0.050 |
Why?
|
| Neuroendocrine Tumors | 1 | 2006 | 634 | 0.050 |
Why?
|
| Cancer Care Facilities | 2 | 2017 | 884 | 0.050 |
Why?
|
| Myocardium | 1 | 2006 | 1313 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2016 | 5178 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2009 | 2518 | 0.040 |
Why?
|
| Phantoms, Imaging | 2 | 2003 | 1271 | 0.040 |
Why?
|
| Barrett Esophagus | 1 | 2005 | 569 | 0.040 |
Why?
|
| SEER Program | 2 | 2015 | 1000 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2012 | 2488 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2020 | 409 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2016 | 1586 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2014 | 1163 | 0.040 |
Why?
|
| Community Networks | 1 | 2018 | 45 | 0.040 |
Why?
|
| Uterine Neoplasms | 1 | 1983 | 545 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2003 | 1090 | 0.040 |
Why?
|
| Antigens, Neoplasm | 2 | 2015 | 1506 | 0.040 |
Why?
|
| Pulmonary Fibrosis | 2 | 2011 | 170 | 0.040 |
Why?
|
| Medicare | 2 | 2015 | 860 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2012 | 355 | 0.040 |
Why?
|
| Obesity | 1 | 2010 | 2884 | 0.040 |
Why?
|
| Motion | 2 | 2008 | 193 | 0.040 |
Why?
|
| Diagnostic Imaging | 2 | 2009 | 1162 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2020 | 6100 | 0.040 |
Why?
|
| Phosphorylation | 3 | 2012 | 4804 | 0.040 |
Why?
|
| Aftercare | 1 | 2018 | 259 | 0.040 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 5687 | 0.040 |
Why?
|
| Recurrence | 2 | 2017 | 4758 | 0.040 |
Why?
|
| Myelography | 1 | 1976 | 16 | 0.040 |
Why?
|
| Intervertebral Disc Displacement | 1 | 1976 | 28 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 827 | 0.040 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 77 | 0.040 |
Why?
|
| Perfusion | 2 | 2008 | 293 | 0.030 |
Why?
|
| Steroids | 1 | 2018 | 356 | 0.030 |
Why?
|
| Protective Factors | 1 | 2016 | 106 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2016 | 3033 | 0.030 |
Why?
|
| Consolidation Chemotherapy | 1 | 2016 | 155 | 0.030 |
Why?
|
| DNA Repair | 3 | 2011 | 1872 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2016 | 235 | 0.030 |
Why?
|
| Netherlands | 1 | 2015 | 83 | 0.030 |
Why?
|
| CD8 Antigens | 1 | 2015 | 170 | 0.030 |
Why?
|
| Cell Movement | 2 | 2013 | 2466 | 0.030 |
Why?
|
| Fatigue | 2 | 2016 | 1239 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2013 | 598 | 0.030 |
Why?
|
| Thyroxine | 1 | 2015 | 116 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2010 | 1819 | 0.030 |
Why?
|
| Lumbar Vertebrae | 1 | 1976 | 245 | 0.030 |
Why?
|
| Accreditation | 1 | 2015 | 126 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 1183 | 0.030 |
Why?
|
| ras Proteins | 2 | 2012 | 770 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 1077 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 1304 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 2330 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2002 | 1270 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2015 | 288 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 151 | 0.030 |
Why?
|
| Genetic Therapy | 3 | 2008 | 1616 | 0.030 |
Why?
|
| Troponin I | 1 | 2014 | 127 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 233 | 0.030 |
Why?
|
| Liposomes | 1 | 2015 | 684 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2015 | 403 | 0.030 |
Why?
|
| Patient Positioning | 1 | 2015 | 195 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2017 | 825 | 0.030 |
Why?
|
| Pain Management | 1 | 2019 | 668 | 0.030 |
Why?
|
| Retreatment | 1 | 2014 | 452 | 0.030 |
Why?
|
| Hypothyroidism | 1 | 2015 | 204 | 0.030 |
Why?
|
| Monocytes | 1 | 2017 | 788 | 0.030 |
Why?
|
| Bridged-Ring Compounds | 1 | 2013 | 183 | 0.030 |
Why?
|
| Phenotype | 2 | 2014 | 6295 | 0.030 |
Why?
|
| Pyrrolidinones | 1 | 2013 | 61 | 0.030 |
Why?
|
| Cesium Radioisotopes | 1 | 2012 | 39 | 0.030 |
Why?
|
| Immune System | 1 | 2014 | 279 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 607 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 2013 | 128 | 0.030 |
Why?
|
| CpG Islands | 1 | 2014 | 633 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 383 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 5159 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2012 | 231 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 750 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 1053 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 756 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2015 | 395 | 0.030 |
Why?
|
| Vital Capacity | 1 | 2012 | 131 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2014 | 343 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2015 | 1021 | 0.030 |
Why?
|
| Radiotherapy Setup Errors | 1 | 2012 | 80 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2013 | 264 | 0.030 |
Why?
|
| DNA Ligase ATP | 1 | 2011 | 51 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 992 | 0.030 |
Why?
|
| Ku Autoantigen | 1 | 2011 | 79 | 0.030 |
Why?
|
| Esophageal Stenosis | 1 | 2011 | 83 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2011 | 62 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2015 | 657 | 0.020 |
Why?
|
| Disease Management | 1 | 2017 | 1052 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 1033 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2013 | 311 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2005 | 1382 | 0.020 |
Why?
|
| Contrast Media | 2 | 2008 | 1472 | 0.020 |
Why?
|
| Bronchography | 1 | 2010 | 25 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 203 | 0.020 |
Why?
|
| Standard of Care | 1 | 2012 | 243 | 0.020 |
Why?
|
| Antigens, Nuclear | 1 | 2011 | 119 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1217 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 1519 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 2 | 2003 | 483 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 698 | 0.020 |
Why?
|
| Anilides | 1 | 2013 | 268 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2013 | 256 | 0.020 |
Why?
|
| Mediastinum | 1 | 2012 | 268 | 0.020 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 430 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 677 | 0.020 |
Why?
|
| Biological Transport | 1 | 2012 | 597 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 1688 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2008 | 2054 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2010 | 209 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2011 | 170 | 0.020 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2012 | 332 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2010 | 77 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 1062 | 0.020 |
Why?
|
| Synchrotrons | 1 | 2009 | 35 | 0.020 |
Why?
|
| Cartilage | 1 | 2010 | 128 | 0.020 |
Why?
|
| Quinolines | 1 | 2013 | 383 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2018 | 2086 | 0.020 |
Why?
|
| Equipment Safety | 1 | 2009 | 64 | 0.020 |
Why?
|
| Ablation Techniques | 1 | 2011 | 148 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2013 | 588 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2014 | 2074 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2011 | 324 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 987 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 276 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2009 | 239 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 1959 | 0.020 |
Why?
|
| Reoperation | 1 | 2013 | 1382 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2015 | 1146 | 0.020 |
Why?
|
| Gases | 1 | 2008 | 36 | 0.020 |
Why?
|
| Bronchi | 1 | 2010 | 326 | 0.020 |
Why?
|
| DNA Helicases | 1 | 2011 | 434 | 0.020 |
Why?
|
| Scattering, Radiation | 1 | 2009 | 316 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 589 | 0.020 |
Why?
|
| Integrin beta Chains | 1 | 2008 | 34 | 0.020 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2008 | 107 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 719 | 0.020 |
Why?
|
| Radiology Information Systems | 1 | 2008 | 114 | 0.020 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2008 | 163 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 1399 | 0.020 |
Why?
|
| Water | 1 | 2009 | 361 | 0.020 |
Why?
|
| Pain | 1 | 2016 | 1658 | 0.020 |
Why?
|
| Mice, Inbred CBA | 1 | 2007 | 78 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2010 | 478 | 0.020 |
Why?
|
| Diaphragm | 1 | 2008 | 181 | 0.020 |
Why?
|
| Exhalation | 1 | 2007 | 60 | 0.020 |
Why?
|
| Deglutition | 1 | 2008 | 171 | 0.020 |
Why?
|
| Angiogenic Proteins | 1 | 2007 | 37 | 0.020 |
Why?
|
| Asthma | 1 | 2015 | 871 | 0.020 |
Why?
|
| Synaptophysin | 1 | 2006 | 79 | 0.020 |
Why?
|
| Biological Products | 1 | 2010 | 274 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2015 | 1589 | 0.020 |
Why?
|
| Chromogranin A | 1 | 2006 | 65 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 995 | 0.020 |
Why?
|
| Chromogranins | 1 | 2006 | 84 | 0.020 |
Why?
|
| Pericardium | 1 | 2008 | 157 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 2450 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2007 | 306 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2006 | 58 | 0.020 |
Why?
|
| Consensus | 1 | 2010 | 978 | 0.020 |
Why?
|
| Point Mutation | 1 | 2009 | 769 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2009 | 829 | 0.020 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2008 | 275 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2006 | 79 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2006 | 129 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 1178 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2006 | 224 | 0.020 |
Why?
|
| Pyridines | 1 | 2013 | 1244 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 423 | 0.020 |
Why?
|
| Equipment Design | 1 | 2009 | 1204 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2008 | 310 | 0.020 |
Why?
|
| Pressure | 1 | 2006 | 215 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2006 | 239 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 2005 | 159 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 1258 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2006 | 226 | 0.020 |
Why?
|
| Stomach | 1 | 2008 | 387 | 0.020 |
Why?
|
| Cadherins | 1 | 2008 | 660 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2010 | 1038 | 0.020 |
Why?
|
| Hypertension | 1 | 2015 | 1503 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2009 | 938 | 0.020 |
Why?
|
| Oncolytic Virotherapy | 1 | 2008 | 280 | 0.020 |
Why?
|
| Life Tables | 1 | 2004 | 120 | 0.020 |
Why?
|
| Telomerase | 1 | 2008 | 525 | 0.020 |
Why?
|
| BCG Vaccine | 1 | 1988 | 399 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 1082 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 2 | 2011 | 3976 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2010 | 2588 | 0.020 |
Why?
|
| Mutagens | 1 | 2005 | 187 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 2437 | 0.020 |
Why?
|
| beta Catenin | 1 | 2008 | 688 | 0.020 |
Why?
|
| Craniotomy | 1 | 2006 | 304 | 0.020 |
Why?
|
| Dyspnea | 1 | 2007 | 416 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 1225 | 0.010 |
Why?
|
| Awards and Prizes | 1 | 2005 | 98 | 0.010 |
Why?
|
| Chylous Ascites | 1 | 1983 | 25 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 694 | 0.010 |
Why?
|
| Sclerosis | 1 | 1983 | 84 | 0.010 |
Why?
|
| Random Allocation | 1 | 1985 | 703 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 177 | 0.010 |
Why?
|
| Adolescent | 2 | 2016 | 31252 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 334 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 3203 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 4744 | 0.010 |
Why?
|
| Immobilization | 1 | 2003 | 93 | 0.010 |
Why?
|
| Topotecan | 1 | 2003 | 239 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 1323 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2004 | 295 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2003 | 200 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2010 | 2203 | 0.010 |
Why?
|
| Membrane Proteins | 2 | 2003 | 2819 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2003 | 367 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 891 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 2314 | 0.010 |
Why?
|
| RNA Interference | 1 | 2006 | 1408 | 0.010 |
Why?
|
| Skin Diseases | 1 | 2005 | 349 | 0.010 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 321 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 726 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 1363 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2003 | 665 | 0.010 |
Why?
|
| Artifacts | 1 | 2004 | 532 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2003 | 749 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2005 | 1555 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2008 | 1443 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2003 | 716 | 0.010 |
Why?
|
| Technetium | 1 | 1979 | 77 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2005 | 1085 | 0.010 |
Why?
|
| Cell Survival | 1 | 2005 | 3045 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2004 | 795 | 0.010 |
Why?
|
| Lymphoma | 1 | 2007 | 1467 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1979 | 660 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2005 | 1960 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 3001 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2004 | 3005 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2005 | 830 | 0.010 |
Why?
|
| Rats | 1 | 2006 | 6086 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1983 | 1039 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 1756 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 3639 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1979 | 509 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2008 | 5270 | 0.010 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1977 | 388 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 6150 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1988 | 4638 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2007 | 3578 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2008 | 5767 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 1977 | 129 | 0.000 |
Why?
|